Abstract
The COVID-19 pandemic has burdened most of the health systems around the world. Governments, especially in resource-constrained low- and middle-income countries, are finding it hard to meet the health needs of their nationals. Patent exclusive rights further add to the cost of healthcare by allowing supra-competitive prices of protected technologies. Parallel importation of patented health technologies is a legitimate policy option to obtain patented health technologies at a reduced price. This paper examines the legality and practical significance of parallel trade of patented medicines as a price-reducing policy option and evaluates some of the practical hurdles in the actual use of this important public health flexibility. This study supports the adoption of international exhaustion of patent rights as a mandatory rule for the international trading system.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.